
Opinion|Videos|January 13, 2025
The Role of Posttransplant Cyclophosphamide in Patients With cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how he uses cyclophosphamide to treat patients with chronic graft-vs-host disease (cGVHD), particularly in specific cases where other therapies may not be effective. He reviews the study design and methods of recent research investigating cyclophosphamide in cGVHD management, emphasizing its importance in optimizing treatment strategies.
Advertisement
Video content above is prompted by the following:
- Which patients with chronic graft-vs-host disease (cGVHD) do you treat with cyclophosphamide in your clinical practice?
- What were this abstract’s study design and methods, and why was it important to investigate for cGVHD management?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer
3
Team-Based Precision Oncology: Advancing Value and Access in Cancer Care
4
Navigating Costs and Logistics of Cellular Therapies, ADCs, and Novel Diagnostics in Cancer Care
5














































